The biological role and regulation of versican levels in cancer

Increased expression of the proteoglycan, versican is strongly associated with poor outcome for many different cancers. Depending on the cancer type, versican is expressed by either the cancer cells themselves or by stromal cells surrounding the tumor. Versican plays diverse roles in cell adhesion, proliferation, migration and angiogenesis, all features of invasion and metastasis. These wide ranging functions have been attributed to the central glycosaminoglycan-binding region of versican, and to the N-(G1) and C-(G3) terminal globular domains which collectively interact with a large number of extracellular matrix and cell surface structural components. Here we review the recently identified mechanisms responsible for the regulation of versican expression and the biological roles that versican plays in cancer invasion and metastasis. The regulation of versican expression may represent one mechanism whereby cancer cells alter their surrounding microenvironment to facilitate the malignant growth and invasion of several tumor types. A greater understanding of the regulation of versican expression may contribute to the development of therapeutic methods to inhibit versican function and tumor invasion.

[1]  C. Bandtlow,et al.  Brain derived versican V2 is a potent inhibitor of axonal growth. , 2000, Journal of cell science.

[2]  J. Couchman,et al.  Association of versican with dermal matrices and its potential role in hair follicle development and cycling. , 1995, The Journal of investigative dermatology.

[3]  T. Wight,et al.  Versican degradation and vascular disease. , 2006, Trends in cardiovascular medicine.

[4]  P. Katonis,et al.  Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. , 2008, Biochimica et biophysica acta.

[5]  E. Schönherr,et al.  Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. , 1991, The Journal of biological chemistry.

[6]  M. Mörgelin,et al.  Distribution of PG-M/Versican Variants in Human Tissues andde Novo Expression of Isoform V3 upon Endothelial Cell Activation, Migration, and Neoangiogenesis in Vitro * , 2002, The Journal of Biological Chemistry.

[7]  D Heinegård,et al.  The Proteoglycans Aggrecan and Versican Form Networks with Fibulin-2 through Their Lectin Domain Binding* , 2001, The Journal of Biological Chemistry.

[8]  T. Wight,et al.  Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Nakamura,et al.  Glioma invasiveness responds variably to irradiation in a co-culture model. , 2007, International journal of radiation oncology, biology, physics.

[10]  S. Hockfield,et al.  Brain-enriched Hyaluronan Binding (BEHAB)/Brevican Cleavage in a Glioma Cell Line Is Mediated by a Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) Family Member* , 2000, The Journal of Biological Chemistry.

[11]  Pier Andrea Nicolosi,et al.  Proteoglycans in the Control of Tumor Growth and Metastasis Formation , 2008, Connective tissue research.

[12]  A. Bosserhoff,et al.  The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-β2 , 2007, British Journal of Cancer.

[13]  Yaou Zhang,et al.  The G3 Domain of Versican Enhances Cell Proliferation via Epidermial Growth Factor-like Motifs* , 1998, The Journal of Biological Chemistry.

[14]  A. Colombatti,et al.  The globular domains of PGM/versican modulate the proliferation‐apoptosis equilibrium and invasive capabilities of tumor cells , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  M. Waters,et al.  Growth factor modulation of mitogenic responses and proteoglycan synthesis by human periodontal fibroblasts , 1998, Journal of cellular physiology.

[16]  R. Contreras,et al.  Differentiation of EL4 lymphoma cells by tumoral environment is associated with inappropriate expression of the large chondroitin sulfate proteoglycan PG‐M and the tumor‐associated antigen HTgp‐175 , 1998, International journal of cancer.

[17]  William Arbuthnot Sir Lane,et al.  Glial hyaluronate-binding protein: a product of metalloproteinase digestion of versican? , 1995, The Biochemical journal.

[18]  M. Akens,et al.  The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis , 2007, Breast Cancer Research.

[19]  S. Mukaratirwa,et al.  Mutual paracrine effects of colorectal tumour cells and stromal cells: modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture , 2005, International journal of experimental pathology.

[20]  Jiaquan Xu,et al.  Deaths: final data for 2005. , 2008, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[21]  G. Miserocchi,et al.  The sensitivity of versican from rabbit lung to gelatinase A (MMP‐2) and B (MMP‐9) and its involvement in the development of hydraulic lung edema , 1999, FEBS letters.

[22]  Shuhei Yamada,et al.  Oversulfated Chondroitin/Dermatan Sulfates Containing GlcAβ1/IdoAα1–3GalNAc(4,6-O-disulfate) Interact with L- and P-selectin and Chemokines* , 2002, The Journal of Biological Chemistry.

[23]  K. Almholt,et al.  Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model , 2008, Molecular Cancer Therapeutics.

[24]  D. Horsfall,et al.  Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer , 2004, Clinical Cancer Research.

[25]  A. Scarpa,et al.  Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[27]  I. Stamenkovic,et al.  Inhibition of tumor growth in vivo by hyaluronan oligomers , 1998, International journal of cancer.

[28]  A. Skubitz,et al.  Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells , 2004, Clinical & Experimental Metastasis.

[29]  D. Kletsas,et al.  The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. , 2006, Biochimica et biophysica acta.

[30]  W. Knudson,et al.  Assembly of a chondrocyte-like pericellular matrix on non-chondrogenic cells. Role of the cell surface hyaluronan receptors in the assembly of a pericellular matrix. , 1991, Journal of cell science.

[31]  S. Shapiro,et al.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Horsfall,et al.  Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  E. De Pauw,et al.  Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method , 2007, Proteomics.

[34]  S. Hockfield,et al.  BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. , 1996, Cancer research.

[35]  A. Yee,et al.  The interaction of versican with its binding partners , 2005, Cell Research.

[36]  D. Horsfall,et al.  Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility* , 2007, Journal of Biological Chemistry.

[37]  D. Horsfall,et al.  Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation , 2007, The Prostate.

[38]  F. Wright,et al.  Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Allahverdian,et al.  Androgen Receptor Regulation of the Versican Gene through an Androgen Response Element in the Proximal Promoter* , 2007, Journal of Biological Chemistry.

[40]  A. Bassols,et al.  Versican is differentially expressed in human melanoma and may play a role in tumor development. , 2002, The American journal of pathology.

[41]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[42]  S. Ochsner,et al.  Hormone-regulated expression and localization of versican in the rodent ovary. , 2003, Endocrinology.

[43]  V. Kosma,et al.  High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma , 2006, Journal of Clinical Pathology.

[44]  松本 和 Distinct interaction of versican/ PG-M with hyaluronan and link protein , 2004 .

[45]  J. Sandy,et al.  ADAMTS4 (aggrecanase-1) cleaves human brain versican V2 at Glu405-Gln406 to generate glial hyaluronate binding protein. , 2004, The Biochemical journal.

[46]  J. Kirkwood,et al.  Integrins and cancer. , 2007, Oncology.

[47]  A. Bassols,et al.  V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis , 2006, Laboratory Investigation.

[48]  E. Ruoslahti,et al.  Multiple domains of the large fibroblast proteoglycan, versican. , 1989, The EMBO journal.

[49]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[50]  K. Tashiro,et al.  Versican Interacts with Chemokines and Modulates Cellular Responses* , 2001, The Journal of Biological Chemistry.

[51]  G. Maira,et al.  Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme , 2008, Cancer.

[52]  V. Lee,et al.  Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. , 1999, Journal of neuropathology and experimental neurology.

[53]  A. Miller-Larsson,et al.  Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol. , 2006, American journal of respiratory cell and molecular biology.

[54]  J. Fischer,et al.  Versican V1 Proteolysis in Human Aorta in Vivo Occurs at the Glu441-Ala442 Bond, a Site That Is Cleaved by Recombinant ADAMTS-1 and ADAMTS-4* , 2001, The Journal of Biological Chemistry.

[55]  M. Mörgelin,et al.  Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/versican and aggrecan. , 2000, Development.

[56]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Wight,et al.  Versican: a versatile extracellular matrix proteoglycan in cell biology. , 2002, Current opinion in cell biology.

[58]  S. Hockfield,et al.  BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion , 2008, Journal of Neuro-Oncology.

[59]  Anthony J. Guidi,et al.  Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  K. Nabeshima,et al.  Cohort migration of carcinoma cells: differentiated colorectal carcinoma cells move as coherent cell clusters or sheets. , 1999, Histology and histopathology.

[61]  M. Iruela-Arispe,et al.  Proteolytic cleavage of versican during cardiac cushion morphogenesis , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[62]  D. Zimmermann,et al.  Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. , 1994, The Journal of biological chemistry.

[63]  H. Larjava,et al.  Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. , 1991, The Journal of biological chemistry.

[64]  V. Kosma,et al.  Versican in epithelial ovarian cancer: Relation to hyaluronan, clinicopathologic factors and prognosis , 2003, International journal of cancer.

[65]  B. McManus,et al.  Versican: signaling to transcriptional control pathways. , 2006, Canadian journal of physiology and pharmacology.

[66]  N. Karamanos,et al.  Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. , 1999, Biochimie.

[67]  F. Hamdy,et al.  The expression and regulation of ADAMTS‐1, ‐4, ‐5, ‐9, and ‐15, and TIMP‐3 by TGFβ1 in prostate cells: relevance to the accumulation of versican , 2005, The Prostate.

[68]  R. Page,et al.  Interleukin-1 beta regulation of fibroblast proteoglycan synthesis involves a decrease in versican steady-state mRNA levels. , 1993, The Biochemical journal.

[69]  A. Alexandrova,et al.  Evolution of cell interactions with extracellular matrix during carcinogenesis , 2008, Biochemistry (Moscow).

[70]  R. Fritsche-Danielson,et al.  Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[71]  D. Horsfall,et al.  Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  J. Lemire,et al.  Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro , 2002, Journal of cellular physiology.

[73]  D. Horsfall,et al.  Modulation of prostate cancer cell attachment to matrix by versican. , 2003, Cancer research.

[74]  A. Hongo,et al.  Prognostic significance of stromal versican expression in human endometrial cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  V. Kosma,et al.  Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study , 2004, Journal of Clinical Pathology.

[76]  M. Yamagata,et al.  Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PG-M/versican. , 1994, Journal of cell science.

[77]  M. Yamagata,et al.  Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. , 1986, The Journal of biological chemistry.

[78]  Christina K. Chan,et al.  Interleukin-1beta selectively decreases the synthesis of versican by arterial smooth muscle cells. , 2007, Journal of cellular biochemistry.

[79]  F. Lu,et al.  Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. , 2004, Molecular biology of the cell.

[80]  A. Bassols,et al.  V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential , 2005, International journal of cancer.

[81]  E. Schönherr,et al.  Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. , 1997, Archives of biochemistry and biophysics.

[82]  David E. Misek,et al.  Analysis of Tumor-Host Interactions by Gene Expression Profiling of Lung Adenocarcinoma Xenografts Identifies Genes Involved in Tumor Formation , 2005, Molecular Cancer Research.

[83]  Jonathan R Pollack,et al.  A transcriptional response to Wnt protein in human embryonic carcinoma cells , 2002, BMC Developmental Biology.

[84]  A. Skubitz,et al.  Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers , 2004, Clinical & Experimental Metastasis.

[85]  Yaou Zhang,et al.  Cell adhesion and proliferation mediated through the G1 domain of versican , 1999, Journal of cellular biochemistry.

[86]  M. Miyasaka,et al.  Binding of a Large Chondroitin Sulfate/Dermatan Sulfate Proteoglycan, Versican, to L-selectin, P-selectin, and CD44* , 2000, The Journal of Biological Chemistry.

[87]  A. Theocharis,et al.  Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. , 2003, Anticancer research.

[88]  V. Kosma,et al.  Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. , 2005, Human pathology.

[89]  J. Fawcett,et al.  Versican Is Upregulated in CNS Injury and Is a Product of Oligodendrocyte Lineage Cells , 2002, The Journal of Neuroscience.

[90]  T. Wight,et al.  Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. , 2001, Archives of biochemistry and biophysics.

[91]  W. Paulus,et al.  Differential Expression of Versican Isoforms in Brain Tumors , 1996, Journal of neuropathology and experimental neurology.

[92]  R. Timpl,et al.  Fibulin-1 Is a Ligand for the C-type Lectin Domains of Aggrecan and Versican* , 1999, The Journal of Biological Chemistry.

[93]  S. Paris,et al.  Hyaluronectin modulation of lung metastasis in nude mice. , 2006, European journal of cancer.

[94]  S. Baylin,et al.  Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. , 1999, Cancer research.

[95]  T. Ratliff CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. , 2005, The Journal of urology.

[96]  T. Oegema,et al.  Hyaluronan Synthase Elevation in Metastatic Prostate Carcinoma Cells Correlates with Hyaluronan Surface Retention, a Prerequisite for Rapid Adhesion to Bone Marrow Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[97]  H K Dressman,et al.  Identification of genes associated with ovarian cancer metastasis using microarray expression analysis , 2006, International Journal of Gynecologic Cancer.

[98]  E. Ruoslahti,et al.  The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[99]  A. Tsatsakis,et al.  Transforming Growth Factor‐β as a key molecule triggering the expression of versican isoforms v0 and v1, Hyaluronan Synthase‐2 and synthesis of Hyaluronan in Malignant Osteosarcoma cells , 2006 .

[100]  Peter Friedl,et al.  Tube travel: the role of proteases in individual and collective cancer cell invasion. , 2008, Cancer research.

[101]  J. Slingerland,et al.  The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. , 2005, Molecular biology of the cell.

[102]  Burton B. Yang,et al.  β1-Integrin-mediated Glioma Cell Adhesion and Free Radical-induced Apoptosis Are Regulated by Binding to a C-terminal Domain of PG-M/Versican* , 2002, The Journal of Biological Chemistry.

[103]  A. J. Day,et al.  Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. , 2003, European journal of biochemistry.

[104]  S. Ochsner,et al.  Processing and Localization of ADAMTS-1 and Proteolytic Cleavage of Versican during Cumulus Matrix Expansion and Ovulation* , 2003, Journal of Biological Chemistry.

[105]  D. Horsfall,et al.  Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non‐organ confined disease , 2005, The Prostate.

[106]  Maree H. Poniris,et al.  A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. , 2006, The Journal of allergy and clinical immunology.

[107]  Freddie C Hamdy,et al.  Screening for prostate cancer: an update. , 2008, European urology.

[108]  H. Friess,et al.  Pancreatic tumor cells influence the composition of the extracellular matrix. , 2004, Biochemical and biophysical research communications.

[109]  Burton B. Yang,et al.  The ability of versican to simultaneously cause apoptotic resistance and sensitivity. , 2007, Cancer research.

[110]  K. Kurth,et al.  Role of proteoglycans in cell adhesion of prostate cancer cells: From review to experiment , 2004, Urological Research.

[111]  M. Yamagata,et al.  Selective distributions of proteoglycans and their ligands in pericellular matrix of cultured fibroblasts. Implications for their roles in cell-substratum adhesion. , 1993, Journal of cell science.

[112]  H. Sasamura,et al.  Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. , 2001, Journal of the American Society of Nephrology : JASN.

[113]  T. Wight,et al.  Regulation of Proteoglycan Synthesis by Leukotriene D4 and Epidermal Growth Factor in Bronchial Smooth Muscle Cells Materials and Methods , 2022 .

[114]  S. Berceli,et al.  Increased Plasmin and Serine Proteinase Activity During Flow-Induced Intimal Atrophy in Baboon PTFE Grafts , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[115]  R. Ádány,et al.  Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. , 1990, The Journal of biological chemistry.

[116]  G. Westergren-Thorsson,et al.  Alteration of proteoglycan synthesis in human lung fibroblasts induced by interleukin‐1β and tumor necrosis factor‐α , 2000, Journal of cellular biochemistry.

[117]  S. Hockfield,et al.  Glial Tumor Invasion: A Role for the Upregulation and Cleavage of BEHAB/Brevican , 2001, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[118]  N. Nakashima,et al.  Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG- M/versican , 2004, The Histochemical Journal.

[119]  M. Miyasaka,et al.  Identification and characterization of ligands for L-selectin in the kidney. I. Versican, a large chondroitin sulfate proteoglycan, is a ligand for L-selectin. , 1999, International immunology.

[120]  C. Burger,et al.  Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  D. Horsfall,et al.  Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. , 2001, Cancer research.

[122]  E. Ruoslahti,et al.  Hyaluronate binding properties of versican. , 1992, The Journal of biological chemistry.

[123]  A. Hongo,et al.  Versican expression in human cervical cancer. , 2007, European journal of cancer.

[124]  B. McManus,et al.  Regulation of the Versican Promoter by the β-Catenin-T-cell Factor Complex in Vascular Smooth Muscle Cells* , 2005, Journal of Biological Chemistry.

[125]  Sabrina Cattaruzza,et al.  Proteoglycan control of cell movement during wound healing and cancer spreading. , 2005, Matrix biology : journal of the International Society for Matrix Biology.

[126]  R. Kerbel,et al.  Versican/PG‐M G3 domain promotes tumor growth and angiogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[127]  M. Stack,et al.  Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion , 2007, Nature Cell Biology.

[128]  Christina K. Chan,et al.  Interleukin‐1β selectively decreases the synthesis of versican by arterial smooth muscle cells , 2007 .